48 results about "Teratoma" patented technology

The invention discloses a method for preparing a population of?human pluripotent stem cells and the application thereof. The preparation of stem cells is characterized by comprising the following steps: CD151<+>, CD31<->, Sox<2+> pluripotent stem cells are separated and collected from human umbilical cord and or placenta tissues; the cells adhere to grow in a culture vessel under a predetermined condition and expand through passage 20 or above to be still stable in gene expression. The population of cells of this invention do not form teratoma after injection into animals. The human pluripotent stem cells highly express CD151, OCT4 and Sox-2 as specific markers of embryonic stem cells, as well as specific markers of epidermic cells, endothelial cells, thrombocytes, dendritic cells, while lack expression of CD31, CD34, CD45 and HLA-II. The pluripotent stem cells are also characterized as being able to adhere to tissue culture plastic and having the potential to differentiate into three germ layers: endoderm, mesoderm and ectoderm. These pluripotent stem cells are able to be used as carrier cells of gene therapy and for the treatment of diseases caused by cell damage or cell aging. The present invention provides a method of isolating, purifying and culturally expanding of a population of human pluripotent stem cell for preparing the high purity injection preparation. The preparation of stem cells has a good therapeutic effect on the treatment of diseases caused by cell damage or cell aging in animal and human clinical trials. The preparation also has no toxic side effect and no immune rejection.

A method for expansion of human embryonic stem (hES) cells in a medium including human umbilical cord-derived mesenchymal stem cells (HUCMSCs) as a feeder is provided. The human embryonic stem cells (hES) maintain the features of embryonic stem cells in the medium, such as pluripotency, unlimited undifferentiated proliferation and normal karyotypes. Also provided is a method for non-tumorigenic expansion of the human embryonic stem cells (hES) that is free from forming teratoma.

The present invention relates to a composition for skin regeneration, using a culture medium or a secretion in the culture of an embryonic stem cell-derived endothelial progenitor cell, and to the use thereof. As the present invention uses the secretion in the culture as a medicine and not the embryonic stem cell-derived endothelial progenitor cell itself, the risk of teratoma formation is prevented, and angiogenic activity is promoted to achieve improved effectiveness in healing wounds and burn wounds. The composition of the present invention, when used as a material in cosmetics, increases collagen synthesis and thus prevents skin aging. Particularly, the composition of the present invention in which the secretion in the culture is concentrated into a high concentration provides superior wound-healing effects as compared to a conventional human growth hormone (hGH).

The invention provides a serum-free feed layer-free mouse induced pluripotent stem cell (iPSC) induction medium and a culture method using the same. The medium is a serum-free feed layer-free medium,can be used as an induction medium for mouse somatic cell-induced formation of iPSCs, improves iPS cell induction efficiency, shortens the induction time and can be used for culturing mouse iPSCs. Inthe culture system, after 20 passages of mouse iPSCs, the mouse iPSCs retain stem cell pluripotency and the normal cell karyotype. An internal teratoma experiment result shows that after culture for 20 passages, the mouse iPSCs in the culture system retain a trilaminar differentiation potential of PSCs.

The invention discloses a method for inducing bovine induced pluripotent stem cells, which comprises: constructing a fusion protein lentivirus expression vector for inducing bovine induced pluripotent stem cells by using an exogenous defined factor and enhanced green fluorescent protein (EGPF) reporter gene; cultivating and passing bovine fetus fibroblast cells in which the fusion protein of the exogenous defined factor is expressed; gradually separating and cultivating cell colonies with clearly defined colony borders; and obtaining the bovine induced pluripotent stem cells, if the growth states of the cell colonies are stable, the karyotype is normal, the cell colonies are negative in alkaline phosphatase test, the expression of proteins Oct4, Nanog and SSEA-1 is positive in immunocyte chemical tests, teratoma having three embryonic layers can be differentiated in vivo, and the result proves the separated cell conolnies have the characteristics of embryonic stem cells.

The invention discloses a porcine somatic cell mutagensis method. Porcine embryonic fibroblasts are infected and acted a plurality of times by using slow viruses carrying enhanced green fluorescent protein markers; the original fibrous growth forms of the porcine embryonic fibroblasts are changed step by step under a growing environment condition of a stem cell culture solution to form nest-like cell colonies; separated, cultured and sub-cultured cell colonies have clear edges and boundaries, stable growth states and normal karyotypes; alkaline phosphatase is expressed to be positive; immunocytochemical detection shows that Oct4, Nanog and SSEA-1 proteins are expressed to be positive; teratoma comprising three embryonic layers is formed by differentiation in vivo; and the result proves that the mutagenic porcine somatic cells have the stem cell properties under the action of the slow viruses.

The present invention provides a rat embryonic stem cell characterized by having the following properties of (a) expressing Oct3 / 4 gene and Nanog gene, (b) positive for alkaline phosphatase activity, (c) having an embryoid body forming ability, (d) expressing SSEA (Stage-Specific Embryonic Antigen)-1 and SSEA-4, (e) having the same number of chromosomes as does a normal rat cell, (f) capable of being subcultured and holding the undifferentiated state, (g) having in vitro pluripotency, (h) having a potential to differentiate for cells of three embryonic germ lineages, (i) having teratoma formation ability, and (j) having an ability to produce a chimeric rat, a method of establishing the aforementioned rat embryonic stem cell and the like.

The invention relates to a novel method for culturing a multipotential stem cell without serum and a feeder layer. The method is stable, reliable, and can culture the multipotential stem cell for a long time and also can maintain the self-renewing of the multipotential stem cell. The method is characterized in that a culture system with clear chemical components and without serum and the feeder layer is adopted to perform suspension culture on the multipotential stem cell. According to the morphology of cultured stem cells after 15 generations, mRNA (Messenger Ribonucleic Acid) and protein expression of multipotential marker molecule, and analysis on cell chromatin karyotype, such novel generation system can maintain the properties of the multipotential stem cell during long-term culture. In addition, the differentiative potential of the multipotentail stem cell is further verified by 15-generation suspension culture in an in-vitro embryoid body formation experiment and an in-vivo teratoma formation experiment.

Compositions and methods are provided for depletion of pluripotent cells. In one embodiment of the invention, methods are provided for depletion of pluripotent cells from a mixed population of differentiated cells and stem cells, to provide a population of cells substantially free of pluripotent stem cells. Monoclonal antibodies useful in depletion and in identification of pluripotent stem cells are also provided.

An in vitro human neural multipotent, unipotent, or somatic cell possessing all of the following characteristics: is derived from the reprogramming of a somatic cell, a progenitor cell or a stem cell that exhibits at least a transient increase in intracellular levels of at least one reprogramming agent; is not differentiated from a pluripotent cell; expresses one or more markers of a multipotent, unipotent or somatic cell not characteristic of a neural stem cell, neural precursor cell, neural progenitor cell, neuroblast, or neuron; is not a cancerous cell; is stable and not artificially maintained by forced gene expression and may be maintained in standard neural stem cell media or neural media; and does not exhibit uncontrolled growth, teratoma formation, and tumor formation in vivo; wherein the cell comprises at least one polypeptide or an expression vector encoding at least one polypeptide selected from the group consisting of: Musashi1 (Msi1); Ngn2; Msi1 and Ngn2; Msi1 and methyl-CpG binding domain protein 2 (MBD2); Ngn2 and MBD2; Msi1, Ngn2 and MBD2; Achaete-Scute Homolog 1 (Ascl1); Msi1, Ngn2 and Ascl1; Msi1, Ngn2, MBD2 and Ascl1; Sox2; Msi1, Ngn2 and Sox2; and Msi1, Ngn2, MBD2 and Sox2; wherein the expression vector is transiently expressed.

The invention relates to a device for selecting stem cells with a serum free medium for amplification of stem cells. The invention also relates to a method of treating or preventing diseases caused by cancer-related stem cells. The invention further provides a method of enhancing radiosensitivity of cancer-related stem cells comprising radiotherapy with resveratrol, and the cancer-related stem cell has stronger drug resistance. The present invention further provides that resveratrol promotes differentiation and inhibits teratoma / tumor formation in induced pluripotent stem cells (iPS) and embryonic stem cells.

The present invention relates to a composition for inducing direct transdifferentiation of a somatic cell into a vascular progenitor cell and a use thereof and, more specifically, to a composition for inducing direct transdifferentiation of a somatic cell into a vascular progenitor cell, a pharmaceutical composition for the prevention or treatment of ischemic vascular diseases, a cell therapeutic agent for the prevention or treatment of ischemic vascular diseases, a composition for screening a therapeutic drug for ischemic vascular diseases, a 3D printing biological material composition for the production of an artificial tissue for the treatment of ischemic vascular diseases, and a method for direct transdifferentiation of a somatic cell into a vascular progenitor cell. By producing a vascular progenitor cell by direct transdifferentiation of a somatic cell according to the present invention, it is possible to reduce the production period of the vascular progenitor cell and to avoid the formation of teratoma, which is a side effect of an induced pluripotent stem cell, thereby minimizing the side effects of a stem cell therapeutic agent.

A method for expansion of human embryonic stem (hES) cells in a medium including human umbilical cord-derived mesenchymal stem cells (HUCMSCs) as a feeder is provided. The human embryonic stem cells (hES) maintain the features of embryonic stem cells in the medium, such as pluripotency, unlimited undifferentiated proliferation and normal karyotypes. Also provided is a method for non-tumorigenic expansion of the human embryonic stem cells (hES) that is free from forming teratoma.

The invention provides a method for producing polypeptide protein products and nucleic acid products having reduced levels of antigenicity in an animal being treated with a biologic product. Somatic cells are isolated from an animal, transformed into pluripotent stem cells, transfected with a nucleic acid(s) of interest, and re-differentiated towards somatic cells known to be high level producers of the desired nucleic acid product. The invention can be used to derive a general cell line to treat populations, racial specific cell lines to treat ethnic groups, or patient specific cell lines to treat individuals. Additionally, the invention provides a method to allow induced pluripotent stem cells to be re-differentiated towards their somatic cell of origin so that the cells can be used to therapeutically treat an animal without resulting teratoma formation.